Industry News
Pharmaceutical Industry News
With the new “Operation Access…
With the new “Operation Access Now” program, BlinkRx claims drugmakers will be able to launch direct-to-patient sales of their products within 21 days.
Pfizer and Astellas’ Padcev,…
Pfizer and Astellas' Padcev, combined with Keytruda, improved the survival outcomes of muscle-invasive bladder cancer patients who are ineligible for standard cisplatin-based chemotherapy.
The lack of an earnings call…
The lack of an earnings call accompanying Summit’s second-quarter results came after Bloomberg last month reported that the company was engaged in high-stakes licensing talks for its PD-1xVEGF antibody ivonescimab.
Four years on from its original…
Four years on from its original “Bent Carrot” ad, Endo has returned to the campaign for a new TV spot that looks at how a man overcame his concerns and sought treatment for Peyronie’s disease.
The ability to inoculate young…
The ability to inoculate young children against COVID-19 in the U.S. may be diminished this fall as the FDA weighs whether to renew the emergency green light for the vaccine currently cleared in the broadest
Sanner, a German device CDMO and…
Sanner, a German device CDMO and healthcare packaging specialist that has been on an expansion tear the last few years, named an interim chief executive to replace Dr. Johannis Willem van Vliet.
Why Young Children May Not Get Covid Shots This Fall
Under Robert F. Kennedy Jr., federal officials may withdraw an endorsement for the vaccine in younger children.
How Rick Perry Became a Fervent Advocate for the Psychedelic Ibogaine
The former Texas governor and Trump energy secretary has now dedicated his life to promoting the powerful psychedelic ibogaine.
Argenx has found a new doubles…
Argenx has found a new doubles partner for its work to raise awareness of myasthenia gravis.
The FDA on Tuesday signed off on…
The FDA on Tuesday signed off on Insmed’s brensocatib to treat non-cystic fibrosis bronchiectasis (NCFBE) in adults and kids ages 12 and up. The medicine is now available by prescription in the U.S. through a
Cold Chain Technologies is…
Cold Chain Technologies is eliminating 82 positions at its headquarters in Franklin, Massachusetts, according to a state Worker Adjustment and Retraining Act (WARN) report. The company said it is shifting some of its operations from
“At the FDA’s request, Dr….
“At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,” an HHS spokesperson told Fierce Pharma.
Will MAHA Change America?
The outsider critique of the medical establishment has always struggled to offer an alternative vision that’s rigorous rather than credulous.
Why Are Tariffs on Switzerland So High?
President Trump sees Switzerland as doing too little to address its trade deficit with the U.S., a gap he focused on as he imposed a 39% tariff on Swiss goods.
While most of Gilead’s…
While most of Gilead’s second-quarter presentation focused on its excitement over the launch of game-changing HIV PrEP drug Yeztugo, there was a disquieting sidebar as sales of its cell therapies were down by 7%.
“Free Mind” is the first…
“Free Mind” is the first public health campaign launched by the CDC since Robert F. Kennedy Jr. was appointed secretary of the U.S. Department of Health and Human Services.
After telegraphing an…
After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain CALD patients.
Pfizer and BioNTech have settled…
Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.S. The deal will see BioNTech pay out cash and extend royalties from sales of its COVID vaccine to CureVac
Sanofi is pulling its PCSK9 drug…
Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs may eventually reach 250%. A venture capital crunch in Southeast Asia is pushing investors to be more
Genmab and AbbVie have presented…
Genmab and AbbVie have presented new data that could help grow the reach of their blood cancer drug Epkinly in follicular lymphoma. The partners are anticipating a November 30 FDA decision date to move an